Early Phase 1 Depression and Anxiety Trial, Recruiting NCT06636812 Sponsor: University of Oxford Condition: Depression and Anxiety
Back to Depression And Anxiety

Early Phase 1 Depression and Anxiety Trial, Recruiting

NCT06636812
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to give their informed consent to take part (for those aged 16 or 17, both their own agreement and a parent or legal guardian's consent are required)
  • People who do not smoke, or who smoke fewer than 5 cigarettes per day
  • People who are able to travel to Oxford for appointments, where reasonable travel costs are covered
  • People who are willing to provide their GP's contact details

Who may not be able to join:

  • People who have been diagnosed with, or currently have, a major mental health condition (such as severe psychiatric illness, or alcohol or drug dependence), based on a screening assessment
  • People who have a close family member (parent, sibling, or child) with a severe psychiatric illness
  • People who have taken any medication affecting the brain or nervous system in the past 6 weeks, including as part of another study
  • People who are currently taking blood pressure medication or heart medication, especially a drug called aliskiren or beta blockers
  • People who have been diagnosed with low fluid levels or dehydration in their body
  • People whose kidneys are not working well enough, based on a blood test done at screening (confirm with trial site for specific threshold details)
  • People who have significantly high potassium levels in their blood (confirm with trial site for specific threshold details)
  • People who have very low blood pressure, based on repeated measurements taken under standardised conditions
  • People who weigh less than 35 kg
  • People who have ever had epilepsy or another neurological condition (such as ADHD or autism)
  • People who have ever had a severe allergic skin/throat swelling reaction (angioedema), narrowed kidney arteries, heart valve disease, or repeated episodes of dizziness upon standing
  • People who have ever had a serious systemic infection, or a significant liver, heart, lung, kidney, brain, metabolic, hormone-related, or breathing condition that, in the investigator's opinion, could put them at risk or affect the study results
  • People with significant hearing loss that is not corrected by a hearing device
  • People who do not have sufficient written or spoken English skills
  • People who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Andrea Reinecke, PhD, University of Oxford

Phone: +44 01865 618320

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Registry
ClinicalTrials.gov
Start date
7 March 2024
Est. completion
31 December 2025

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Fear Extinction

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov